PLoS ONE (Jan 2023)

Therapeutic efficacy of Chloroquine for the treatment of uncomplicated Plasmodium vivax infection in Shewa Robit, Northeast Ethiopia.

  • Habtamu Belay,
  • Megbaru Alemu,
  • Tadesse Hailu,
  • Hussein Mohammed,
  • Heven Sime,
  • Henok Hailegeorgies,
  • Bokretsion Gidey,
  • Mebrahtom Haile,
  • Gudissa Assefa,
  • Worku Bekele,
  • Mihreteab Alebachew Reta,
  • Andargachew Almaw Tamene,
  • Geremew Tasew,
  • Ashenafi Assefa

DOI
https://doi.org/10.1371/journal.pone.0277362
Journal volume & issue
Vol. 18, no. 1
p. e0277362

Abstract

Read online

BackgroundThe development of drug resistance to chloroquine is posing a challenge in the prevention and control efforts of malaria globally. Chloroquine is the first-line treatment for uncomplicated P.vivax in Ethiopia. Regular monitoring of anti-malarial drugs is recommended to help early detection of drug-resistant strains of malaria parasites before widely distributed. The emergence of P.vivax resistance to chloroquine in the country endangers the efficacy of P.vivax treatment. This study aimed to assess the therapeutic efficacy of chloroquine among uncomplicated P.vivax infections at Shewa Robit Health Center, northeast Ethiopia.MethodsOne-arm in vivo prospective chloroquine efficacy study was conducted from November 2020 to March 2021. Ninety participants aged between 16 months to 60 years confirmed with P.vivax mono-infection microscopically were selected and treated with a 25 mg/kg standard dose of chloroquine over three days. Thick and thin blood smears were prepared and examined. Clinical examination was performed over 28 follow-up days. Hemoglobin concentration level was measured on days 0, 14, and 28.ResultOf the 90 enrolled participants, 86 (96%) completed their 28 days follow-up period. The overall cure rate of the drug was 98.8% (95% CI: 95.3-100%). All asexual stages and gametocytes were cleared within 48 hours with rapid clearance of fever. Hemoglobin concentration had significantly recovered between days 0 and 14, 0 and 28, and 14 and 28 days (P = 0.032, PConclusionThe present study revealed that chloroquine remains an efficacious and safe drug in the study setting for treating uncomplicated P.vivax in the study area. Large-scale continuous surveillance is needed to monitor the development of resistance in due time.